CN117243838A - Whitening composition and preparation method and application thereof - Google Patents
Whitening composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN117243838A CN117243838A CN202210651993.3A CN202210651993A CN117243838A CN 117243838 A CN117243838 A CN 117243838A CN 202210651993 A CN202210651993 A CN 202210651993A CN 117243838 A CN117243838 A CN 117243838A
- Authority
- CN
- China
- Prior art keywords
- composition
- phenethyl resorcinol
- salt
- whitening
- resorcinol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 230000002087 whitening effect Effects 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title abstract description 7
- VNXWANZMRATDQM-UHFFFAOYSA-N 2-(2-phenylethyl)benzene-1,3-diol Chemical compound OC1=CC=CC(O)=C1CCC1=CC=CC=C1 VNXWANZMRATDQM-UHFFFAOYSA-N 0.000 claims abstract description 53
- 230000000694 effects Effects 0.000 claims abstract description 33
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 claims abstract description 32
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 102000003425 Tyrosinase Human genes 0.000 claims abstract description 22
- 108060008724 Tyrosinase Proteins 0.000 claims abstract description 22
- WQXNXVUDBPYKBA-UHFFFAOYSA-N Ectoine Natural products CC1=NCCC(C(O)=O)N1 WQXNXVUDBPYKBA-UHFFFAOYSA-N 0.000 claims description 18
- 239000006071 cream Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000002674 ointment Substances 0.000 claims description 6
- 230000003061 melanogenesis Effects 0.000 claims description 5
- 239000000049 pigment Substances 0.000 claims description 5
- 239000004909 Moisturizer Substances 0.000 claims description 3
- 230000002421 anti-septic effect Effects 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 239000003205 fragrance Substances 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 230000001333 moisturizer Effects 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- -1 pH adjusters Substances 0.000 claims description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 36
- 208000003351 Melanosis Diseases 0.000 abstract description 4
- 238000012546 transfer Methods 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 33
- 239000000047 product Substances 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 22
- 230000005764 inhibitory process Effects 0.000 description 22
- 230000000052 comparative effect Effects 0.000 description 19
- 238000012360 testing method Methods 0.000 description 10
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- 239000002609 medium Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000002752 melanocyte Anatomy 0.000 description 4
- PQSXNIMHIHYFEE-UHFFFAOYSA-N 4-(1-phenylethyl)benzene-1,3-diol Chemical compound C=1C=C(O)C=C(O)C=1C(C)C1=CC=CC=C1 PQSXNIMHIHYFEE-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 241000021559 Dicerandra Species 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 235000010654 Melissa officinalis Nutrition 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- JCGHAEBIBSEQAD-UUUCSUBKSA-N eugeniin Chemical compound OC1=C(O)C(O)=CC(C(=O)O[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)[C@@H]3OC(=O)C4=CC(O)=C(O)C(O)=C4C4=C(O)C(O)=C(O)C=C4C(=O)OC[C@H]3O2)OC(=O)C=2C=C(O)C(O)=C(O)C=2)=C1 JCGHAEBIBSEQAD-UUUCSUBKSA-N 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229940106025 phenylethyl resorcinol Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- PHOLIFLKGONSGY-CSKARUKUSA-N (e)-(3-methyl-1,3-benzothiazol-2-ylidene)hydrazine Chemical compound C1=CC=C2S\C(=N\N)N(C)C2=C1 PHOLIFLKGONSGY-CSKARUKUSA-N 0.000 description 1
- OTPDWCMLUKMQNO-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine Chemical compound C1NCC=CN1 OTPDWCMLUKMQNO-UHFFFAOYSA-N 0.000 description 1
- YPUZOECTETYPRF-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine-2-carboxylic acid Chemical compound OC(=O)C1NCC=CN1 YPUZOECTETYPRF-UHFFFAOYSA-N 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000187398 Streptomyces lividans Species 0.000 description 1
- JCGHAEBIBSEQAD-ANGOHYEVSA-N Tellimagrandin II Natural products O=C(O[C@@H]1[C@@H](OC(=O)c2cc(O)c(O)c(O)c2)O[C@@H]2[C@@H]([C@@H]1OC(=O)c1cc(O)c(O)c(O)c1)OC(=O)c1c(c(O)c(O)c(O)c1)-c1c(O)c(O)c(O)cc1C(=O)OC2)c1cc(O)c(O)c(O)c1 JCGHAEBIBSEQAD-ANGOHYEVSA-N 0.000 description 1
- 229920001990 Tellimagrandin II Polymers 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000001058 brown pigment Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
The application discloses a composition with a whitening function, which comprises the ectoin or the salt thereof and the phenethyl resorcinol, and can effectively inhibit the generation or transfer of melanin through the reasonable proportion of the ectoin or the salt thereof and the phenethyl resorcinol, so that the composition can obviously inhibit the activity of tyrosinase and inhibit the generation of melanin, the whitening and freckle removing effects are obvious, and the effect is better than the use effect of the independent components. The application also discloses a preparation method and application of the composition.
Description
Technical Field
The application relates to the field of cosmetics and skin care products, in particular to a whitening composition, a preparation method and application thereof.
Background
The skin color of normal people is mainly determined by various pigment conditions and distribution conditions in the skin, the thickness of the skin, the scattering phenomenon of light on the skin surface and the like. Generally, the color spots and shade are related to melanin, which is mainly produced by melanocytes and is classified into several types of melanin or eugeniin, brown pigment and neuro pigment. The melanin formation process of the skin includes a complex series of processes such as migration of melanocytes, division and maturation of melanocytes, formation of melanosomes, running of melanin granules, and excretion of melanin.
The existing raw materials with whitening effect mainly achieve the whitening effect based on the following aspects: (1) accelerating cell death and detachment to improve skin state, and has effects of smoothing, tendering and softening skin surface, and reducing skin pigmentation and color spots; (2) inhibiting tyrosinase activity in a concentration range without melanocyte toxicity, and blocking synthesis of dopa and dopaquinone, thereby inhibiting melanin production. (3) Inhibit tyrosinase production, etc.
The english INCI name for phenethyl resorcinol is Phenylethyl Resorcinol, a phenolic starting material developed by Symrise. It inhibits tyrosinase activity by blocking tyrosine conversion to L-DOPA, which is 22 times more active than kojic acid in vitro mushroom tyrosinase and in vitro epidermis models.
Disclosure of Invention
However, higher concentrations of phenethyl resorcinol are required to exert tyrosinase inhibitory activity, however, the high concentrations of phenethyl resorcinol have a certain irritation to skin and are costly, so that the irritation is reduced while the whitening effect is maintained, and the method has important research significance for application of the phenethyl resorcinol in cosmetics.
Therefore, the application provides a novel whitening composition containing phenethyl resorcinol, which is compounded with ectoine or salts thereof to achieve the whitening effect and reduce the use concentration of the phenethyl resorcinol.
Specifically, the application adopts the following technical scheme,
1. a composition having a whitening effect, the composition comprising ectoine or a salt thereof and phenethyl resorcinol.
2. The composition according to item 1, wherein the mass ratio of the ectoin or salt thereof and the phenethyl resorcinol is 1:0.00004-0.001, preferably 1:0.0001-0.0005.
3. The composition according to item 1 or 2, wherein the ectoin or a salt thereof is 0.01% to 5% by mass, preferably 0.01% to 1% by mass, further preferably 0.1% to 1% by mass of the phenethyl resorcinol is 0.00001% to 0.5% by mass, preferably 0.00001% to 0.00005% by mass of the composition.
4. The composition of any one of items 1-3, consisting of ectoin or a salt thereof and phenethyl resorcinol.
5. Use of the composition of any one of claims 1-4 for skin whitening, preferably for reducing tyrosinase activity and/or reducing melanogenesis.
6. Use of the composition according to any one of claims 1 to 5 in a skin care product, preferably water, cream, ointment, cream.
7. A skin care product comprising the composition of any one of items 1-4 or a composition prepared by the method of item 5.
8. The skin care product according to item 7, which is water, cream, ointment, or cream.
9. The skin care product according to item 7 or 8, further comprising antioxidants, antiseptic and antifungal agents, moisturizers, surfactants, pH regulators, fragrances, pigments, and functional aids.
Effects of the invention
According to the composition with the whitening function, through reasonable proportion of the ectoin or the salt thereof and the phenethyl resorcinol, the active ingredients complement each other, the composition can be synergistically enhanced, and all-around multi-angle inhibition of melanin generation or transfer is realized through different ways or mechanisms, so that the composition can remarkably inhibit the activity of tyrosinase, inhibit the generation of melanin, has remarkable whitening and freckle removing effects, and has better effect than the use effect of the independent components.
The composition is applied to various skin care products, so that the prepared product has high safety performance and obvious whitening and freckle removing effects.
Meanwhile, the content of the phenethyl resorcinol used in the composition is obviously lower than the use amount commonly used in the market, so that the cost is saved, the damage to skin cells is smaller, and the sufficient whitening effect is ensured.
Detailed Description
Exemplary embodiments of the present application are described below, including various details of embodiments of the present application to facilitate understanding, which should be considered as merely exemplary. Accordingly, one of ordinary skill in the art will recognize that various changes and modifications of the embodiments described herein can be made without departing from the scope and spirit of the present application. Also, descriptions of well-known functions and constructions are omitted in the following description for clarity and conciseness.
The application provides a composition with a whitening effect, which comprises ectoine and phenethyl resorcinol.
The chemical formula of the Ectoine (Ectoine) is 2-methyl-1, 4,5, 6-tetrahydropyrimidine-4-carboxylic acid, which is also called tetrahydropyrimidine, and is a novel water-soluble zwitterionic amino acid derivative discovered in 1985. The ectoine, also called as tetrahydropyrimidine carboxylic acid, is an important substance for maintaining osmotic pressure balance, and has a unique molecular structure so that the ectoine has strong water molecule complexing capability. The ectoin can be used as a stabilizer to protect enzymes, DNA, cells and the like against high salinity, drying, freezing, high temperature and other adverse environments, and plays roles in adverse resistance assistance and the like. The skin moisturizing agent is an excellent moisturizing agent for skin, can improve the immunity protection capability of skin cells, increase the cell repair capability, effectively resist invasion of microorganisms and allergens, play roles of antiallergic, anti-inflammatory, repairing and protecting, and strengthen the barrier of microecology, and has been widely applied to health care, life science and cosmetic industries. The exendin used in the composition of the present application is not limited and may be any commercially available or synthetic exendin meeting the above definition.
The exendin or salt thereof may be selected from exendin, hydroxy exendin or exendin methyl ester.
The chemical formula of the phenethyl resorcinol (PER) is 4- (1-phenethyl) 1, 3-benzenediol, the corresponding English INCI name is Phenylethyl Resorcinol, the crystalline solid with low odor inhibits tyrosinase activity by blocking tyrosine from being converted into L-DOPA, the activity of the crystalline solid is 22 times of that of kojic acid in an in-vitro mushroom tyrosinase model and an in-vitro epidermis model, and the crystalline solid is one of the most effective reported tyrosinase inhibitors, is a high-efficiency skin whitening agent, and is widely used for various whitening, freckle-removing and anti-aging products. The phenethyl resorcinol used in the compositions of the present application is not limited and may be any commercially available or synthetic phenethyl resorcinol that meets the above definition. In a preferred embodiment, the present application uses phenolic starting materials developed by Symrise, inc., as a derivative of fat-soluble resorcinol.
In a preferred embodiment, the composition provided herein comprises at least one of ectoin and phenethyl resorcinol in a mass ratio of 1:0.00001-0.001, for example, 1:0.00001, 1:0.00002, 1:0.00003, 1:0.00004, 1:0.00005, 1:0.00006, 1:0.00007, 1:0.00008, 1:0.00009, 1:0.0001, 1:0.00015, 1:0.0002, 1:0.00025, 1:0.0003, 1:0.00035, 1:0.0004, 1:0.00045, 1:0.0005, 1:0.00055, 1:0.0006, 1:0.00065, 1:0.0007, 1:0.00075, 1:0.0008, 1:0.00085, 1:0.00095, and preferably 1:0.00095: 0.0001-0.0005.
In a preferred embodiment, the content of the ectoin or the salt thereof is 0.01% to 5% by mass based on the mass of the composition, for example, may be 0.01%, 0.05%, 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45%, 0.5%, 0.55%, 0.6%, 0.65%, 0.7%, 0.75%, 0.8%, 0.85%, 0.9%, 0.95%, 1.0%, 1.5%, 2.0%, 2.5%, 3.0%, 3.5%, 4.0%, 4.5%, 5.0%, preferably 0.01% to 1%, and more preferably 0.1% to 1%;
the mass percentage of the phenethyl resorcinol is 0.00001% -0.5%. For example, 0.00001%, 0.000015%, 0.00002%, 0.000025%, 0.00003%, 0.000035%, 0.00004%, 0.000045%, 0.00005%, 0.00006%, 0.00007%, 0.00008%, 0.00009%, 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, and preferably 0.00001% -0.00005%.
In a preferred embodiment, the composition consists only of ectoin or a salt thereof and phenethyl resorcinol.
The present application further provides the use of any of the present compositions as described above in skin whitening, in particular in reducing tyrosinase activity and/or reducing melanogenesis.
The whitening composition provided by the application is a core whitening composition, which can be overlapped with any substance in any form during application, including but not limited to mixed use, overlapped coating use, interval use and the like. The mixing means may be any mixing means known in the art.
The present application further provides the use of any of the present compositions as described above in a skin care product, preferably water, cream, ointment, cream.
Such applications include, but are not limited to, the addition of the compositions provided herein having enhanced cellular energy and enhanced skin resistance to skin care products, direct combination with skin care products, indirect combination with other skin care products.
For example, in one specific embodiment, the whitening composition provided herein is first self-mixed, i.e., after having been uniformly mixed with ectoin or a salt thereof and phenethyl resorcinol, added to the skin care product.
In one embodiment, the ectoin or its salt in the whitening composition of the present application is dissolved in a proper manner, the phenethyl resorcinol is dissolved in a proper manner, and then the two dissolved substances are added to the skin care product after being uniformly mixed.
In a specific embodiment, the ectoin or a salt thereof in the whitening composition of the present application is dissolved in an appropriate manner, added to the skin care product, and the phenethyl resorcinol is dissolved in an appropriate manner, and then added to the skin care product.
In a specific embodiment, the phenethyl resorcinol in the whitening compositions of the present application is dissolved in a suitable manner and added to the skin care product, and the ectoin or salt thereof is dissolved in a suitable manner and then added to the skin care product.
In a specific embodiment, the whitening composition of the present application may be added to any one of the steps in the preparation process of the care product after being uniformly mixed.
In a specific embodiment, the exendin or its salt and the phenethyl resorcinol in the whitening composition of the present application may be added to any one of the steps in the preparation process of the care product, respectively, and the order of addition of the exendin or its salt and the phenethyl resorcinol is not limited.
The skin care products include, but are not limited to, water, creams, ointments, creams, essences, sunscreens, oils, body-refreshing, bathing, periocular skin care, facial masks, facial washes, cleansing, foundations, foundation pads, rouges, body-applied make-up, eyebrows, eye shadows, eyelids, eye hair, eye makeup removers, lip balms, lip gloss oils, general lip balms, lip pencil.
The present application further provides a skin care product comprising any of the compositions described above.
In a specific embodiment, the skin care product further comprises antioxidants, antiseptic and mildew inhibitors, moisturizers, surfactants, pH modifiers, fragrances, pigments, and functional aids.
According to a large number of experimental researches, the whitening composition is formed by reasonably proportioning the ectoine and the phenethyl resorcinol, the whitening effect of the composition is better than that of any one of the components in the range of ensuring the safety of the use amount, the inhibition rate of the whitening composition is 25%, the inhibition rate of the whitening composition is improved by 5 times compared with that of the ectoine or the salt thereof or the phenethyl resorcinol which is singly used, the inhibition rate of the melanin is 19%, and compared with that of the ectoine or the salt thereof or the phenethyl resorcinol which is singly used, the maximum improvement of the whitening composition is 6 times, so that the whitening composition has a better superposition effect.
Examples
Example 1
B16 cell complete medium: RPMI 1640 medium (containing 10% FBS, 1% Streptomyces lividans)
Dissolving in B16 culture medium according to the concentration of Ectoine (Hua Xi organism) to obtain component A,
dissolving phenethyl resorcinol (Dexin) in absolute ethanol, and diluting with culture medium according to the concentration gradient in the following table to obtain component B.
And uniformly mixing the component A and the component B to obtain the composition.
Examples 2 to 9
The preparation was carried out as in example 1, wherein the contents of Ectoine and phenethyl resorcinol are shown in Table 1.
Blank control
Blank 1 was the same B16 cell complete medium as in example 1, without addition of ethandine;
blank 2 was the same absolute ethanol as in example 1, with no phenethyl resorcinol added.
TABLE 1
Test example 1 toxicity test
Sample treatment: b16 cells (mouse melanoma cells) were co-cultured with the compositions obtained in examples and comparative examples and a blank control for 1 day, the medium was removed, MTT (thiazole blue) was added, the supernatant was carefully aspirated after 3 hours, dimethyl sulfoxide (DMSO) was added, OD value detection was performed at 550nm with an enzyme-labeled instrument, after the background was removed by reading, and the relative cell activity was expressed as a percentage after homogenization based on the control.
The growth and metabolism of B16 cells is normally a prerequisite for the detection of the efficacy of the active substance, which is considered to be a non-toxic dose of the active substance if the cell number is not significantly reduced after the addition of the active substance of the experimental group.
Since the two samples have different solubilities, two solvents were selected for dissolution. According to the method, the ethandiol is directly diluted by a culture medium, the phenethyl resorcinol is dissolved by absolute ethyl alcohol and then diluted by the culture medium, so that the solvent control has two groups, and NT is respectively used E With NT P This represents 100%. Sample treatment groups of comparative examples 1-3 containing only exendin were also defined as T E Sample treatment groups of comparative examples 4-6 containing only phenethyl resorcinol were T P ，T E /NT E Ratio of OD values as cell Activity Rate of the Icotolyfactor, T P /NT P The ratio of OD values of (c) was taken as the cell viability of phenethyl resorcinol.
The specific test results are shown in table 2 below.
TABLE 2
The cell activity rate in the cytotoxicity test was lower than 80%, and it was considered that there was significant difference from the control to be cytotoxicity, and it can be seen from table 2 that the decrease in cell activity rate was insignificant at the concentration of about 0.1% -1% for the cocaine compared to the untreated (NT) blank group, indicating no toxic effect on cells, and no significant difference between the groups, indicating that the concentration of about 1% or less for the cocaine could be selected for use in the safety range; when the concentration of the phenethyl resorcinol is 0.00001-0.000043%, the decrease of the cell activity rate is not obvious, which shows no toxic effect on cells, and no obvious difference among groups, so that the concentration of the phenethyl resorcinol can be selected and used within a safety range of 0.000043% or less.
Test example 2 tyrosinase activity inhibition test
The testing method comprises the following steps: b16 cells were cultured in T75 flasks with medium to a cell density of about 80%, seeded in 96-well plates at 37 ℃ in 5% co 2 Culturing under the condition. After 24h, the supernatant was aspirated off, and the experimental group was supplemented with complete medium containing samples at various concentrations, while a blank group was set. Placing at 37deg.C and 5% CO 2 Incubators were incubated for 72h. The supernatant was aspirated, the cells were washed twice, and working solution containing Triton100, L-DOPA and MBTH was added. 37 times, 5% CO 2 The mixture was placed in a constant temperature incubator for 30min, OD value was measured at 490nm with an enzyme-labeled instrument, and after the background was removed from the reading, the relative tyrosinase activity was expressed as a percentage after homogenization based on the control. Respectively using NT E With NT P This represents 100%. At the same time define the sample treatment group as T E Or T P ，T E /NT E As the tyrosinase activity rate of the Ictaduone group, T P /NT P As the tyrosinase activity rate of phenethyl resorcinol, T is the ratio of OD values of E+P /NT P The ratio of OD values of (c) was used as the tyrosinase activity rate for the combination of ethandin and phenethyl resorcinol.
Additive effects of the composition we used the formula of gold: q=e (a+b)/(ea+eb-ea×eb) (where Q <0.55 is a pronounced antagonism, q=0.55-0.85 is antagonism, q=0.85-1.15 is addition, Q >1.15 is enhancement).
For example, when the inhibition ratio at the concentration of Ectoine is 5%, such as comparative example 1, and the inhibition ratio at the concentration of phenethyl resorcinol is 0.00001% is 3%, such as comparative example 4, and when the inhibition ratio of Ectoine-0.01% and phenethyl resorcinol-0.00001% used in combination is 10%, such as example 1,
ea=Ectoine-0.01% inhibition = 5%;
eb = phenethyl resorcinol-0.00001% inhibition = 3%;
e (a+b) =Ectoine-0.01% and phenethyl resorcinol-0.00001% in combination with inhibition = 10%,
carry formula to get Q Ectoine-0.01% + phenethyl resorcinol-0.00001% ＝1.27。
The Q values of the above concentration combinations were also obtained according to the above formula.
The specific test results are shown in table 3 below.
TABLE 3 Table 3
| Group of | Sample identification | Tyrosinase activity rate | Tyrosinase inhibition rate | Q |
| Blank control 1 | NT E | 100％ | 0％ | / |
| Comparative example 1 | T E1 | 95％ | 5％ | / |
| Comparative example 2 | T E2 | 92％ | 8％ | / |
| Comparative example 3 | T E3 | 95％ | 5％ | / |
| Blank control 2 | NT P | 100％ | 0％ | / |
| Comparative example 4 | T P1 | 97％ | 3％ | / |
| Comparative example 5 | T P2 | 93％ | 7％ | / |
| Comparative example 6 | T P3 | 95％ | 5％ | / |
| Example 1 | T E+P1 | 90％ | 10％ | 1.27 |
| Example 2 | T E+P2 | 86％ | 14％ | 1.20 |
| Example 3 | T E+P3 | 85％ | 15％ | 1.54 |
| Example 4 | T E+P4 | 81％ | 19％ | 1.77 |
| Example 5 | T E+P5 | 75％ | 25％ | 1.73 |
| Example 6 | T E+P6 | 75％ | 25％ | 1.98 |
| Example 7 | T E+P7 | 83％ | 17％ | 2.17 |
| Example 8 | T E+P8 | 82％ | 18％ | 1.55 |
| Example 9 | T E+P9 | 83％ | 17％ | 1.74 |
The above results illustrate: the concentrations of 0.01%, 0.1% and 1% of the ethandiol are respectively combined with 0.00001%, 0.000021% and 0.000043% of the phenethyl resorcinol, so that tyrosinase activity in the speed limiting step in melanin generation can be effectively inhibited, the inhibition rate of tyrosinase can be up to 25%, and compared with the fact that the inhibition rate of ethandiol or phenethyl resorcinol is only 8% at the highest when the ethandiol or phenethyl resorcinol is singly used, the composition of the ethandiol is improved by more than 5 times at the highest, and has a good superposition effect.
Test example 3 melanin inhibiting test
The testing method comprises the following steps: b16 cells were cultured in T75 flasks with medium until cell density was about 80%, seeded in 6-well plates at 37 ℃ with 5% co 2 Culturing under the condition. After 24h, the supernatant was aspirated off, and the experimental group was supplemented with complete medium containing samples at various concentrations, while a blank group was set. Placing at 37deg.C and 5% CO 2 Incubators were incubated for 72h. Sucking out the supernatant, washing the cells twice, digesting the collected cells with pancreatin, isolatingAfter heart, the supernatant is discarded, a melanin extraction solution containing 1mol/L NaOH and 10% DMSO is added, the mixture is heated for 1 hour in a 90-color water bath, an OD value is detected at 405nm by an enzyme labeling instrument, after the background is removed by reading, the relative melanin generation rate is expressed in percentage by taking control as a reference after homogenization. Respectively using NT E With NT P This represents 100%. At the same time define the sample treatment group as T E Or T P ，T E /NT E As the ratio of OD values of the Ekeduo factor, T P /NT P As the melanin formation rate of the phenethyl resorcinol group, T E+P /NT P The ratio of OD values of (c) was used as the melanogenesis rate of the ecalcine to phenethyl resorcinol composition.
Additive effects of the composition we used the formula of gold: q=e (a+b)/(ea+eb-ea×eb) (where Q <0.55 is a pronounced antagonism, q=0.55-0.85 is antagonism, q=0.85-1.15 is addition, Q >1.15 is enhancement).
For example, the inhibition rate is 3% when the concentration of Ectoine is 0.01%, as in comparative example 1; the inhibition rate at a concentration of 0.00001% of phenethyl resorcinol was 3%, as in comparative example 4; the inhibition rates of the combination of the phenethyl resorcinol-0.00001% and the Ectoine-0.01% are respectively 7%, then,
ea=Ectoine-0.01% inhibition = 3%;
eb = phenethyl resorcinol-0.00001% inhibition = 3%;
e (a+b) =Ectoine-0.01% and phenethyl resorcinol-0.00001% in combination with inhibition=7%,
carry formula to get Q Ectoine-0.01% + phenethyl resorcinol-0.00001% ＝1.18。
The Q values of the above concentration combinations were also obtained according to the above formula.
The specific test results are shown in table 4 below.
TABLE 4 Table 4
| Group of | Sample identification | Melanogenesis rate | Melanin inhibiting rate | Q |
| Blank control 1 | NT E | 100％ | 0％ | / |
| Comparative example 1 | T E1 | 97％ | 3％ | / |
| Comparative example 2 | T E2 | 95％ | 5％ | / |
| Comparative example 3 | T E3 | 95％ | 5％ | / |
| Blank control 2 | NT P | 100％ | 0％ | / |
| Comparative example 4 | T P1 | 97％ | 3％ | / |
| Comparative example 5 | T P2 | 95％ | 5％ | / |
| Comparative example 6 | T P3 | 94％ | 6％ | / |
| Example 1 | T E+P1 | 93％ | 7％ | 1.18 |
| Example 2 | T E+P2 | 91％ | 9％ | 1.15 |
| Example 3 | T E+P3 | 89％ | 11％ | 1.25 |
| Example 4 | T E+P4 | 87％ | 13％ | 1.66 |
| Example 5 | T E+P5 | 88％ | 12％ | 1.23 |
| Example 6 | T E+P6 | 81％ | 19％ | 1.78 |
| Example 7 | T E+P7 | 87％ | 13％ | 1.66 |
| Example 8 | T E+P8 | 88％ | 12％ | 1.23 |
| Example 9 | T E+P9 | 87％ | 13％ | 1.21 |
Analysis of results
The above results illustrate: the concentrations of 0.01%, 0.1% and 1% of the ethandiol are respectively combined with 0.00001%, 0.000021% and 0.000043% of the phenethyl resorcinol, so that melanin generation can be effectively inhibited, the melanin inhibition rate can be up to 19%, and compared with the fact that the inhibition rate of the ethandiol or the phenethyl resorcinol used alone is only 5%, the composition of the ethandiol is improved by more than 6 times at most, and the composition has a better superposition effect.
Although described above in connection with the embodiments of the present application, the present application is not limited to the specific embodiments and fields of application described above, which are intended to be illustrative, instructive, and not limiting. Those skilled in the art, having the benefit of this disclosure, may make numerous forms, and equivalents thereof, without departing from the scope of the invention as defined by the claims.
Claims (9)
1. A composition having a whitening effect, characterized in that the composition comprises ectoine or a salt thereof and phenethyl resorcinol.
2. Composition according to claim 1, characterized in that the mass ratio of the ectoin or salt thereof and the phenethyl resorcinol is 1:0.00001 to 1:0.001, preferably 1:0.0001-0.0005.
3. Composition according to claim 1 or 2, characterized in that the ectoine or its salt is present in an amount of 0.01% to 5% by mass, preferably 0.01% to 1% by mass, further preferably 0.1% to 1% by mass, and the phenethyl resorcinol is present in an amount of 0.00001% to 0.5% by mass, preferably 0.00001% to 0.00005% by mass, based on the mass of the composition.
4. A composition according to any one of claims 1 to 3, characterized in that it consists of ectoine or a salt thereof and phenethyl resorcinol.
5. Use of a composition according to any one of claims 1 to 4 for skin whitening, preferably for reducing tyrosinase activity and/or reducing melanogenesis.
6. Use of a composition according to any one of claims 1 to 5 in a skin care product, preferably water, cream, ointment, cream.
7. A skin care product comprising the composition of any one of claims 1-4.
8. The skin care product according to claim 7, which is water, cream, ointment, or cream.
9. The skin care product according to claim 7 or 8, further comprising antioxidants, antiseptic and mildew inhibitors, moisturizers, surfactants, pH adjusters, fragrances, pigments, and functional aids.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210651993.3A CN117243838A (en) | 2022-06-10 | 2022-06-10 | Whitening composition and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210651993.3A CN117243838A (en) | 2022-06-10 | 2022-06-10 | Whitening composition and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117243838A true CN117243838A (en) | 2023-12-19 |
Family
ID=89128149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210651993.3A Pending CN117243838A (en) | 2022-06-10 | 2022-06-10 | Whitening composition and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117243838A (en) |
-
2022
- 2022-06-10 CN CN202210651993.3A patent/CN117243838A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6339822B2 (en) | Cosmetics | |
| JP2010090069A (en) | Skin-whitening agent and external preparation for skin | |
| CN102215812A (en) | Anti-wrinkle agents | |
| JP2011225564A (en) | Cosmetic | |
| CN112451403B (en) | Application of combination of ectoin and 4-methoxy potassium salicylate in cosmetics | |
| KR20140010543A (en) | A whitening cosmetic composition containing hizikia fusiformis extract | |
| KR102016062B1 (en) | Callus extracts from Citrus junos Siebold ex Tanaka and Pyrus pyrifolia Nakai with Whitening and Anti-wrinkle effect | |
| JP2014240375A (en) | Cosmetic | |
| KR20220068595A (en) | Functional bath cleanser composition comprising plant powder | |
| CN117243838A (en) | Whitening composition and preparation method and application thereof | |
| JPH0987164A (en) | Skin preparation for external use | |
| CN105142727B (en) | Enoxolone Asia amide groups hydroxyproline Arrcostab and its shielded derivative | |
| KR101462692B1 (en) | Skin whitening cosmetics | |
| KR20090089973A (en) | Antioxidation and whitening cosmetic compositions containing extract of isodon inflexus var. canescens | |
| KR102699167B1 (en) | Oat sprout postbiotic composition having skin whitening and wrinkle improvement activity and use thereof | |
| US11433012B2 (en) | Peptides for increasing melanin in melanocytes | |
| US11173108B2 (en) | Skin whitening composition comprising cultured product of pseudoalteromonas peptidolytica or extract thereof | |
| KR102062311B1 (en) | Method for Producing Agaricus Blazei Extract, Extract and Cosmetic Composition Using the Same | |
| WO2005063688A1 (en) | Sphingolipid-rucinol derivatives and composition for skin external use containing the derivatives | |
| JP2023054706A (en) | Skin beauty cosmetic | |
| CN113197788A (en) | Composition for skin whitening and skin care cosmetics | |
| JPH08217620A (en) | Melanogenesis inhibitor and skin cosmetic | |
| TWI426926B (en) | Skin whitening compounds and skin compositions | |
| WO2008018133A1 (en) | Moisturizing agent, cell-activating agent, skin-whitening agent, agent for suppressing triglyceride accumulation, antioxidant and external preparation for skin | |
| KR100892273B1 (en) | Composition of skin external application comprising kaempferol-3-O-rutinoside as active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |